Search Blog
Categories
August 2017
M T W T F S S
« Jul    
 123456
78910111213
14151617181920
21222324252627
28293031  

Tags

DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Axiom Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

By Lundin Law PC

LOS ANGELES, CA / ACCESSWIRE / August 19, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Axiom Holdings, Inc. (”Axiom Holdings” or the ”Company”) (OTC PINK: AIOM) for possible violations of federal securities laws from October 14, 2016 through June 19, 2017, inclusive (the ”Class Period”). Investors who purchased or otherwise acquired Axiom Holdings shares during the Class Period should contact the firm by the August 21, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You may also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Axiom Holdings made false and/or misleading statements, and/or failed to disclose, that: the Company lacked control over the merger process sufficient to ensure that the share exchange agreement with CJC Holdings, Ltd. (”CJC”) would be completed; that the agreement with CJC was never completed; that Axiom Holdings’ issuance of shares to the CJC Shareholders was thus improper; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.

On June 19, 2017, Axiom Holdings announced that it identified discrepancies relating to prior news announcements in response to a subpoena from the SEC. The following day, the Company issued another press release, advising investors that ”it now appears the merger was never completed” and advising investors that it would rescind the shares that were issued to CJC Shareholders in relation to the merger. When this news reached the public, shares of Axiom Holdings lowered in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator located in Los Angeles dedicated to upholding shareholders’ rights.

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 473087

The Middle East and North Africa Healthcare Project Pipeline Valued at $55.2bn

New developments expected to be announced at the Building Healthcare Innovation & Design Show, now co-located with Cityscape Global in 2017

DUBAI, UAE, August 19, 2017 /24-7PressRelease/ —

– New developments expected to be announced at the Building Healthcare Innovation & Design Show, now co-located with Cityscape Global in 2017
– Merger will bring in the region’s most influential decision makers in construction, design and development under one roof
– Building Healthcare’s new congress format to offer 6 dedicated conferences under the theme “Starting with the End in Mind”

As much as $55.2bn worth of healthcare projects are in the pipeline in the Middle East and North Africa (MENA) region in 2017, with major new developments expected to be announced at the forthcoming Building Healthcare Innovation & Design Show.

According to the latest industry estimates, a total of 37 mega hospital projects are already underway in the Gulf region, worth about $28.2bn and are expected to add 22,500 hospital beds to existing capacity (Alpen Capital Healthcare Report). The rest of the year will be even more robust for the healthcare projects market, with major projects being undertaken throughout the region.

In the UAE, some of the high-profile projects include Al Ain Hospital, Al Ain; Burjeel Medical City, Abu Dhabi; Gulf Medical University Hospital, Ajman; Mediclinic Parview Hospital, Dubai and King’s College Hospital, Dubai.

In Saudi Arabia, some of the high-profile projects include King Abdullah Bin Abdulaziz, Project For Development of Security Forces Medical Complexes; King Khaled Medical City, Dammam; King Faisal Medical City, Asir; Mouwasat Hospital, Al Khobar and Amal Mental Health Hospital, Taif.

The MENA region’s premier healthcare build and design show, organised by Informa Life Sciences Exhibitions, the world’s leading publishing and exhibitions company, Building Healthcare Innovation & Design Show will be co-located with Cityscape Global for the 2017 edition of the show which will take place from 11-13 September at the Dubai World Trade Centre. The decision to merge the two independently successful trade shows comes as an effort to create one unified business platform for the full spectrum of the construction, design and development industries in the region.

More than 150 exhibiting companies and 3,800 participants are expected to attend Building Healthcare exhibition and conference to discuss new healthcare projects, best practice in design and construction and source new technologies and services that will maximise facility operations and improve patient experience.

The show, which will have its own area at Cityscape Global, is the only dedicated platform for professionals involved in the build, construction, design and innovation of healthcare facilities.

Meanwhile, Cityscape Global 2017, also organised by Informa, is expected to attract more than 30,000 visitors and showcase 1,000 of ongoing and new real estate projects in the region.

Commenting on the decision to co-locate Building Healthcare with Cityscape Global, Dave Panther, Vice President of Sales at Informa said, “While Cityscape is a powerhouse when it comes to showcasing the best of what the region has to offer in terms of real estate, Building Healthcare does the same for the build, construction, design and innovation of healthcare facilities. By combining these two platforms, we can ensure that professionals from across the full spectrum of the industry will find everything they are looking for during the three-day exhibition and congress. We expect many new infrastructure developments and real estate projects to be announced during the show.”

According to global property consultants JLL, who are the official content partners for Building Healthcare, it is not surprising that more real estate players in MENA are seeking to diversify into the healthcare sector.

“The healthcare sector offers the ability for real estate investors to participate in a growing market backed by the government, where long-term leases can be structured to major regional and international healthcare providers,” said Craig Plumb – Head of Research, MENA – JLL. “From a developer’s perspective, healthcare facilities can contribute to the overall attraction of residential communities and also comprises a potential source of demand for commercial space within office or retail projects. While major hospitals may be too specialist for many contractors, clinics and other less specialist medical uses are well within the capabilities of more general contractors.”

Building Healthcare attendees will also benefit from the new congress format offering six dedicated conference sessions under the theme “Starting with the End in Mind”. The free-to-attend congress provides integrated content addressing the challenges involved throughout the entire lifecycle of a healthcare facility: Vision, Invest, Design, Build, Equip and Manage.

Other new features include a full three-day seminar and workshop schedule that will examine ongoing projects in MENA region, discuss how to invest in new markets and assess case studies of planning, design, and construction that can be used in future projects.

Please visit www.buildinghealthcare-exhibition.com for more information about Building Healthcare Innovation & Design Show.

Building Healthcare Innovation & Design Show
Building Healthcare Exhibition
Construction of healthcare facilities
Designing healthcare facilities
Hospital construction
Middle East healthcare projects

Informa Life Sciences Exhibitions, in charge of the healthcare portfolio within Informa’s Global Exhibitions division, organises 26 exhibitions yearly covering the Middle East, Africa, Asia, Europe and US market, connecting more than 150,000 healthcare professionals worldwide and offering a range of marketing solutions for companies involved with the healthcare sector. Over 100 congresses take place in parallel with the exhibitions.

Informa Life Sciences Exhibitions publishes four international healthcare magazines, offers Dothealth, a healthcare portal showcasing over 40,000 healthcare companies and runs Healthy Change, an online recruitment portal.

www.informalifesciences.com

Food Matters TV: The “Netflix of Health and Wellness”

Producers of acclaimed documentary aim to change how people learn, eat and heal themselves with online streaming TV channel

MOOLOOLABA, AUSTRALIA, August 19, 2017 /24-7PressRelease/ — Food Matters TV (FMTV) is becoming the “Netflix of health and wellness” with its revolutionary platform to help people take control of their health and nutrition.

FMTV is a global online streaming TV channel and curator of hundreds of films and videos on health and nutrition topics. FMTV offers guided programs on subjects including overcoming stress and insomnia, cleansing and detoxing, yoga and exercise, preparing for the birth of a child, and fighting cancer and other diseases – all through healthy eating and lifestyle choices. Healthy recipes, expert interviews with global experts and informative and supportive social communities are a click away.

FMTV is the creation of James Colquhoun and Laurentine ten Bosch, a pair of nutritional consultants turned filmmakers, who saw the life-changing power of good nutrition in their own family. In 2008 James’ father Roy became chronically ill while leading the high-stress life typical of many middle-aged professionals. James and Laurentine quit their jobs and put all their energy and savings into producing “Food Matters” (2008), their internationally acclaimed documentary about the medical and healthcare industries. When they showed the raw footage to Roy, it spurred him to get off prescription drugs, change his diet and restore his health. “Within three months he was back to normal, 50 pounds lighter, and running almost daily after five years bedridden,” James recalls. “The transformation was unbelievable.”

James and Laurentine created the website Food Matters as a one-stop shop for people to educate themselves. The site offers health news and tips, healthy recipes, plus now with Food Matters TV, documentaries and guided programs by renowned experts through a state-of-the art multimedia platform. Food Matters has become a leading resource in the natural health world with over 54 million visitors since 2008. They went on to produce another documentary, “Hungry For Change” (2012) an expose of the food and diet industry, and to expand their health and nutrition offerings with books, apps, foods, websites, articles, and social media, with more than 3.7 million followers worldwide.

FMTV is designed to “seriously revolutionize the way people consume healthcare in the 21st century,” Laurentine says. “We’re allowing people to take their health in their own hands and to start finding answers and solutions from the comfort of their own homes.”

About Food Matters TV: Documentary filmmakers James Colquhoun and Laurentine ten Bosch created Food Matters TV, a revolutionary platform that gives people essential tools to take charge of their health. Their films “Food Matters” and “Hungry For Change” reveal how the foods we eat today are damaging our health. To learn more, visit www.FoodMatters.com and www.FMTV.com.

DoctorConnect Attending Industry Shows in September

Come see our latest features at two Las Vegas shows. New patient surveys and automated reminder service.

LAS VEGAS, NV, August 19, 2017 /24-7PressRelease/ — AdTel International, Inc.’s Doctorconnect.net is an interactive patient communication service using automated two-way text/SMS, voice, and email communications to increase patient and family engagement. Doctorconnect will be attending two Las Vegas shows in September 2017, The International Vision West Expo and Association of Otolaryngology Administrators.

Ross Manley, Vice President of AdTel, said, “AdTel is proud to support these associations and the members by attending these informative conferences. Doctorconnect will be at booth MS4049 at the Vision West Expo 2017 Thursday, September 14 to Saturday, September 16 in the Sands Convention Center. AdTel will at the Association of Otolaryngology Administrators (AOA) show Monday, September 18 to Wednesday September 20 located at the Venetian Resorts. At the AOA 2017 our booth number will be 4106.”

Doctorconnect will demonstrate many new user features and service upgrades. These features include better security with our migration to Microsoft Azure database, integrated payment due notices, lab result notifications, several new API partners, and custom patient surveys by location and provider. The new redesigned survey is specifically tooled to allow you to increase and track patient satisfaction for MIPS as well as measuring performance across providers and locations. Online reputation is including with surveys and will increase your practice ratings on all the major review websites.

International Vision Expos, the worldwide conference and exhibition for eyecare and eyewear, are trade-only events that draw more than 30,000 eyecare professionals each year. Co-owned by Reed Exhibitions and The Vision Council, International Vision Expo gives back to the entire ophthalmic community. Proceeds from International Vision Expo are used by The Vision Council to educate consumers about the importance of vision care and the options in eyewear and other related products. In 2016, The Vision Council reached millions of consumers with its messages through marketing materials, public relations outreach and strategic partnerships. International Vision Expo & Conference is a proud supporter of Think About Your Eyes, a national public awareness campaign, presented by The Vision Council and the American Optometric Association, designed to educate the public on the benefits of vision health and promote the importance of getting an annual comprehensive eye exam. Keep this vital campaign going! Sign up at enroll.thinkaboutyoureyes.com.

DoctorConnect.net is a subsidiary of AdTel International, Inc. that provids automated text, voice or email reminders to patients of upcoming scheduled appointments, reminders of vaccination schedules, re-care reminders, notices of availability of test results, notices of prescription refills, and notices of appointment schedule changes. The system allows patients to confirm appointments automatically or request a change in appointment time if necessary. The service is used by a variety of healthcare providers in a wide range of specialties and general medical practice as well as dentists, veterinarians, chiropractors, therapists, and home health providers.

AdTel International, Inc. is a privately held corporation based in Dallas, Texas that has been providing communication systems through innovative technology since 1992. AdTel may be contacted at 972-503-0717 or via our website www.mydrconnect.com.

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Applied Optoelectronics, Inc. and Encourages Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / August 18, 2017 / Khang & Khang LLP (the ”Firm”) announces the filing of a securities class action lawsuit against Applied Optoelectronics, Inc. (”Applied Optoelectronics” or the ”Company”) (NASDAQ: AAOI). Investors who purchased or otherwise acquired shares between July 13, 2017 and August 3, 2017, inclusive (the ”Class Period”), are encouraged to contact the Firm in advance of the October 4, 2017 lead plaintiff motion deadline.

If you purchased Applied Optoelectronics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Applied Optoelectronics made false and/or misleading statements and/or failed to disclose: that a major customer was reducing its purchases of the Company’s 40G receivers; that the loss of this major customer’s business would have a severe negative impact on the Company’s financial performance; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information was released, shares of Applied Optoelectronics dropped in value materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 473080

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against B Communications Ltd. and Reminds Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / August 18, 2017 / Khang & Khang LLP (the ”Firm”) announces a securities class action lawsuit against B Communications Ltd. (”B Communications” or the ”Company”) (NASDAQ: BCOM). Investors who purchased or otherwise acquired shares from November 7, 2013 through June 19, 2017, inclusive (the ”Class Period”), are encouraged to contact the Firm by the August 28, 2017 lead plaintiff motion deadline.

If you purchased shares of B Communications during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, B Communications made false and/or misleading statements, and/or failed to disclose: that: Shaul Elovitch, the controlling shareholder of Bezeq and B Communications, engaged in illegal conduct in connection with the Bezeq-YES Merger; that discovery of the foregoing conduct would subject B Communications and/or Bezeq to heightened regulatory scrutiny and potential criminal sanctions; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On June 20, 2017, The Times of Israel reported that the Israel Securities Authority (”ISA”) raided the offices of Bezeq and detained Elovitch. The ISA stated that it was investigating ”suspicions of violations of the securities law and the penal code relating to transactions connected to” Elovitch. The Israeli publication Globes reported that the ISA is investigating the Bezeq-Yes Merger, as well as payments the unit made to Eurocom under pressure from Elovitch. Following this news, shares of B Communications dropped in value materially, which caused investors harm according to the lawsuit.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 473088

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / August 18, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (NASDAQ: IPCI). Investors, who purchased or otherwise acquired shares between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 29, 2017 lead
plaintiff motion deadline
.

If you purchased IntelliPharmaCeutics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its New Drug Application (“NDA”) for Rexista; that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that, as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On July 24, 2017, scientists from the Food & Drug Administration (“FDA”) expressed concerns that the Company failed to provide enough data about the abuse potential of its opioid painkilling drug, Rexista. On July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s New Drug Application for Rexista, citing insufficient data regarding the abuse-deterrent properties of the drug as a motivating concern. Upon release of this news, the Company’s share price dropped materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 473082

EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against The Advisory Board Company and Encourages Investors with Losses to Contact the Firm

By Lundin Law PC

LOS ANGELES, CA / ACCESSWIRE / August 18, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against The Advisory Board Company (“Advisory Board” or the “Company”) (NASDAQ: ABCO) regarding possible violations of federal securities laws between January 21, 2015 and February 23, 2016, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the October 2, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Advisory Board made materially false and misleading statements and/or failed to disclose that there were severe integration problems associated with its acquisition of Royall and, as a consequence of these integration problems, the Company had no basis to increase the revenue guidance for Royall during the Class Period. When this information reached the public, shares of Advisory Board dropped in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 473074

UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Mattel, Inc. and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / August 18, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Mattel, Inc. (“Mattel” or the “Company”) (NASDAQ: MAT). Investors, who purchased or otherwise acquired Mattel shares from October 20, 2016 through April 20, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the August 28, 2017 lead plaintiff motion deadline.

If you purchased Mattel shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

The Complaint alleges that, during the Class Period, Mattel made false and/or misleading statements, and/or failed to disclose adverse information, including that the Company’s retail customers had high levels of unsold Mattel products, which exposed it to the heightened risk that it would have to issue its retailers financial concessions to remove the excess inventory, and that the Company would experience slower sales growth in future periods. On April 20, 2017, Mattel announced its first quarter 2017 financial results, reporting declines for its worldwide net sales and gross margins on a year-over-year basis, and an increase of over 158% in its operating loss. These results were much lower than Wall Street consensus estimates. Following this news, Mattel’s stock price decreased materially, which caused investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 473078

DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm

By Lundin Law PC

LOS ANGELES, CA / ACCESSWIRE / August 18, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ: OCUL) regarding possible violations of federal securities laws from May 5, 2017 through July 6, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Ocular shares during the Class Period, should contact the firm before the September 5, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may choose to do nothing and be an absent class member as well.

According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that these manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that, as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information reached the public, shares of Ocular lowered in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was created by Brian Lundin, Esq., a securities litigator located in Los Angeles dedicated to upholding shareholders’ rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 473072